Teva (NYSE:TEVA) presented positive data from a Phase 3 study of its drug Ajovy in the prevention of episodic migraine in ...

Teva’s migraine drug Ajovy (fremanezumab) has moved closer to the EU market after the influential CHMP regulatory committee gave it the green light. The decision paves the way for European ...

Teva’s migraine drug Ajovy (fremanezumab) has been approved in Europe, taking on rivals from the same class from Novartis and Eli Lilly. Novartis already has Aimovig (erenumab) approved in ...

Teva also develops its own branded drugs, including AUSTEDO for movement disorders, AJOVY for migraines, and UZEDY for ...

SPACE study is a phase III trial evaluating AJOVY versus placebo over a 12-week period for the preventive treatment of episodic migraine in children and adolescents. According to the study ...

Analyst evaluates Teva's stock performance and recommends holding due to revenue growth and successful debt reduction efforts ...

Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those ...

AJOVY revenue rose 21% YoY to $137 million ... Teva submitted its generic version of Amgen Inc.’s AMGN osteoporosis drug Prolia to the FDA and European Medicines Agency (EMA) for review.